Monogenic Autoinflammatory Diseases. Disorders of Amplified Danger Sensing and Cytokine Dysregulation

Rheumatic Disease Clinics of North America

Volumn 39, Issue 4, 2013, Pages 701-734

  Montealegre Sanchez, Gina A ^a   Almeida de Jesus, Adriana ^a   Goldbach Mansky, Raphaela ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autoinflammatory diseases; Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE); Cryopyrin associated periodic syndrome (CAPS); Deficiency of the IL 1 receptor antagonist (DIRA); Inflammasome; Intracellular pattern recognition receptors (PRR); Neonatal onset multisystem inflammatory disease (NOMID); Proteasome associated autoinflammatory syndrome (PRAAS)

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1; PLACEBO; RILONACEPT;

AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CARD14 MEDIATED PSORIASIS; CELL ACTIVATION; CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE; CINCA SYNDROME; CLINICAL FEATURE; CYTOKINE RESPONSE; ENTERITIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INTERLEUKIN 36 ANTAGONIST DEFICIENCY; KERATINOCYTE; MAJEED SYNDROME; MONOGENIC AUTOINFLAMMATORY DISEASE; MUCKLE WELLS SYNDROME; NONHUMAN; ONSET AGE; PAPA SYNDROME; PRIORITY JOURNAL; PROTEASOME ASSOCIATED AUTOINFLAMMATORY SYNDROME; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

AUTOINFLAMMATORY DISEASES; CHRONIC ATYPICAL NEUTROPHILIC DERMATOSIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE (CANDLE); CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME (CAPS); DEFICIENCY OF THE IL-1 RECEPTOR ANTAGONIST (DIRA); INFLAMMASOME; INTRACELLULAR PATTERN RECOGNITION RECEPTORS (PRR); NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE (NOMID); PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME (PRAAS);

CARRIER PROTEINS; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS;

EID: 84886800734     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.08.001     Document Type: Review

References (130)

1. Kastner D.L., Aksentijevich I., Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010, 140:784-790.
2. Consortium F.F. Acandidate gene for familial Mediterranean fever. Nat Genet 1997, 17:25-31.
3. Consortium T.I. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997, 90:797-807.
4. McDermott M.F., Aksentijevich I., Galon J., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
5. Drenth J.P., Cuisset L., Grateau G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999, 22:178-181.
6. Frenkel J., Houten S.M., Waterham H.R., et al. Mevalonate kinase deficiency and Dutch type periodic fever. Clin Exp Rheumatol 2000, 18:525-532.
7. Houten S.M., Kuis W., Duran M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
8. Ombrello M.J., Remmers E.F., Sun G., et al. Cold urticaria, immunodeficiency and autoimmunity related to PLCG2 deletions. N Engl J Med 2012, 366(4):330-338.
9. Zhou Q., Lee G.S., Brady J., et al. Ahypermorphic missense mutation in PLCG2, encoding phospholipase Cgamma2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet 2012, 91:713-720.
10. Wise C.A., Gillum J.D., Seidman C.E., et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002, 11:961-969.
11. Henderson C., Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010, 22:567-578.
12. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
13. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
14. Martinon F., Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 2004, 117:561-574.
15. Hoffman H.M., Mueller J.L., Broide D.H., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
16. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
17. Ting J.P., Williams K.L. The CATERPILLER family: an ancient family of immune/apoptotic proteins. Clin Immunol 2005, 115:33-37.
18. Atianand M.K., Fitzgerald K.A. Molecular basis of DNA recognition in the immune system. JImmunol 2013, 190:1911-1918.
19. Bennett L., Palucka A.K., Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. JExp Med 2003, 197:711-723.
20. Crow Y.J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 2011, 1238:91-98.
21. Mariathasan S., Newton K., Monack D.M., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004, 430:213-218.
22. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
23. Chae J.J., Komarow H.D., Cheng J., et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003, 11:591-604.
24. Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009, 7:99-109.
25. Haneklaus M., O'Neill L.A., Coll R.C. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013, 25:40-45.
26. Shimada K., Crother T.R., Karlin J., et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36:401-414.
27. 2+ and cAMP. Nature 2012, 492:123-127.
28. Richards N., Schaner P., Diaz A., et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. JBiol Chem 2001, 276:39320-39329.
29. Chae J.J., Cho Y.H., Lee G.S., et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 2011, 34:755-768.
30. Kuijk L.M., Beekman J.M., Koster J., et al. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008, 112:3563-3573.
31. Mandey S.H., Kuijk L.M., Frenkel J., et al. Arole for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006, 54:3690-3695.
32. Lobito A.A., Kimberley F.C., Muppidi J.R., et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006, 108:1320-1327.
33. Simon A., Park H., Maddipati R., et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci USA 2010, 107:9801-9806.
34. Aksentijevich I., Masters S.L., Ferguson P.J., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. NEngl J Med 2009, 360:2426-2437.
35. Reddy S., Jia S., Geoffrey R., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. NEngl J Med 2009, 360:2438-2444.
36. Donkor J., Zhang P., Wong S., et al. Aconserved serine residue is required for the phosphatidate phosphatase activity but not the transcriptional coactivator functions of lipin-1 and lipin-2. JBiol Chem 2009, 284:29968-29978.
37. Fakas S., Qiu Y., Dixon J.L., et al. Phosphatidate phosphatase activity plays key role in protection against fatty acid-induced toxicity in yeast. JBiol Chem 2011, 286:29074-29085.
38. Valdearcos M., Esquinas E., Meana C., et al. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. JBiol Chem 2012, 287:10894-10904.
39. Infevers: an online database for autoinflammatory mutations. Available at: Accessed May 20, 2013. http://fmf.igh.cnrs.fr/ISSAID/infevers/.
40. Aksentijevich I., Nowak M., Mallah M., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348.
41. Feldmann J., Prieur A.M., Quartier P., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71:198-203.
42. Tanaka N., Izawa K., Saito M.K., et al. High incidence of NLRP3 somatic mosaicismin patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 2011, 63:3625-3632.
43. Arostegui J.I., Aldea A., Modesto C., et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004, 50:4045-4050.
44. Stych B., Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008, 24:1577-1582.
45. Dode C., Le Du N., Cuisset L., et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 2002, 70:1498-1506.
46. Hawkins P.N., Lachmann H.J., Aganna E., et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612.
47. Muckle T.J., Well S.M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. QJ Med 1962, 31:235-248.
48. Aganna E., Martinon F., Hawkins P.N., et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002, 46:2445-2452.
49. Goldbach-Mansky R., Dailey N.J., Canna S.W., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. NEngl J Med 2006, 355:581-592.
50. Sibley C.H., Plass N., Snow J., et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012, 64:2375-2386.
51. Hill S.C., Namde M., Dwyer A., et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 2007, 37:145-152.
52. Hoffman H.M., Throne M.L., Amar N.J., et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 2012, 34:2091-2103.
53. Goldbach-Mansky R., Shroff S.D., Wilson M., et al. Apilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58:2432-2442.
54. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. NEngl J Med 2009, 360:2416-2425.
55. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
56. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
57. Neven B., Marvillet I., Terrada C., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
58. Stoffels M., Szperl A., Simon A., et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis 2013, [Epub ahead of print].
59. Heller H., Sohar E., Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathol Microbiol (Basel) 1961, 24:718-723.
60. Ben-Chetrit E., Levy M. Familial Mediterranean fever. Lancet 1998, 351:659-664.
61. Chae J.J., Aksentijevich I., Kastner D.L. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 2009, 146:467-478.
62. Langevitz P., Zemer D., Livneh A., et al. Protracted febrile myalgia in patients with familial Mediterranean fever. JRheumatol 1994, 21:1708-1709.
63. Gedalia A., Zamir S. Neurologic manifestations in familial Mediterranean fever. Pediatr Neurol 1993, 9:301-302.
64. Tunca M., Akar S., Onen F., et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005, 84:1-11.
65. Touitou I., Sarkisian T., Medlej-Hashim M., et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
66. Lachmann H.J., Goodman H.J., Gilbertson J.A., et al. Natural history and outcome in systemic AA amyloidosis. NEngl J Med 2007, 356:2361-2371.
67. Zemer D., Pras M., Sohar E., et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. NEngl J Med 1986, 314:1001-1005.
68. Moser C., Pohl G., Haslinger I., et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009, 24:676-678.
69. Hashkes P.J., Spalding S.J., Giannini E.H., et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012, 157:533-541.
70. Meinzer U., Quartier P., Alexandra J.F., et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011, 41:265-271.
71. Ozen S., Bilginer Y., Aktay Ayaz N., et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. JRheumatol 2011, 38:516-518.
72. Mitroulis I., Skendros P., Oikonomou A., et al. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis 2011, 70:1347-1348.
73. Seyahi E., Ozdogan H., Celik S., et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006, 24:S99-S103.
74. Ozcakar Z.B., Yuksel S., Ekim M., et al. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol 2012, 31:1267-1271.
75. Hull K.M., Drewe E., Aksentijevich I., et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002, 81:349-368.
76. Jesus A.A., Oliveira J.B., Aksentijevich I., et al. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur J Pediatr 2008, 167:1421-1425.
77. Aksentijevich I., Galon J., Soares M., et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001, 69:301-314.
78. Bulua A.C., Mogul D.B., Aksentijevich I., et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012, 64:908-913.
79. Gattorno M., Pelagatti M.A., Meini A., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:1516-1520.
80. Sacre K., Brihaye B., Lidove O., et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. JRheumatol 2008, 35:357-358.
81. Quillinan N., Mannion G., Mohammad A., et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 2011, 70:1692-1693.
82. Cuisset L., Drenth J.P., Simon A., et al. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur J Hum Genet 2001, 9:260-266.
83. Drenth J.P., Haagsma C.J., van der Meer J.W. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994, 73:133-144.
84. Ammouri W., Cuisset L., Rouaghe S., et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 2007, 46:1597-1600.
85. Simon A., Drewe E., van der Meer J.W., et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004, 75:476-483.
86. Bader-Meunier B., Florkin B., Sibilia J., et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011, 128:e152-e159.
87. van der Hilst J.C., Bodar E.J., Barron K.S., et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008, 87:301-310.
88. Takada K., Aksentijevich I., Mahadevan V., et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003, 48:2645-2651.
89. Rigante D., Ansuini V., Bertoni B., et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006, 27:97-100.
90. Galeotti C., Meinzer U., Quartier P., et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 2012, 51:1855-1859.
91. Ferguson P.J., Chen S., Tayeh M.K., et al. Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). J Med Genet 2005, 42:551-557.
92. Majeed H.A., Kalaawi M., Mohanty D., et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. JPediatr 1989, 115:730-734.
93. Ferguson P.J., El-Shanti H.I. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007, 19:492-498.
94. Jesus A.A., Osman M., Silva C.A., et al. Anovel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis Rheum 2011, 63:4007-4017.
95. Herlin T., Fiirgaard B., Bjerre M., et al. Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis 2013, 72(3):410-413.
96. Miceli-Richard C., Lesage S., Rybojad M., et al. CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-20.
97. Kanazawa N., Okafuji I., Kambe N., et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005, 105:1195-1197.
98. Rose C.D., Arostegui J.I., Martin T.M., et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. Arthritis Rheum 2009, 60:1797-1803.
99. Rose C.D., Martin T.M., Wouters C.H. Blau syndrome revisited. Curr Opin Rheumatol 2011, 23:411-418.
100. Arostegui J.I., Arnal C., Merino R., et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007, 56:3805-3813.
101. Wu Y., Spencer S.D., Lasky L.A. Tyrosine phosphorylation regulates the SH3-mediated binding of the Wiskott-Aldrich syndrome protein to PSTPIP, a cytoskeletal-associated protein. JBiol Chem 1998, 273:5765-5770.
102. Shoham N.G., Centola M., Mansfield E., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003, 100:13501-13506.
103. Yu J.W., Fernandes-Alnemri T., Datta P., et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007, 28:214-227.
104. Wang D., Hoing S., Patterson H.C., et al. Inflammation in mice ectopically expressing human Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne (PAPA) Syndrome-associated PSTPIP1 A230T mutant proteins. JBiol Chem 2013, 288:4594-4601.
105. Demidowich A.P., Freeman A.F., Kuhns D.B., et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012, 64:2022-2027.
106. Stohwasser R., Kuckelkorn U., Kraft R., et al. 20S proteasome from LMP7 knock out mice reveals altered proteolytic activities and cleavage site preferences. FEBS Lett 1996, 383:109-113.
107. Ciechanover A. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Neurodegener Dis 2012, 10:7-22.
108. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007, 35:12-17.
109. Seifert U., Bialy L.P., Ebstein F., et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010, 142:613-624.
110. Agarwal A.K., Xing C., DeMartino G.N., et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet 2010, 87:866-872.
111. Arima K., Kinoshita A., Mishima H., et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci USA 2011, 108:14914-14919.
112. Kitamura A., Maekawa Y., Uehara H., et al. Amutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. JClin Invest 2011, 121:4150-4160.
113. Liu Y., Ramot Y., Torrelo A., et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012, 64:895-907.
114. Livingston J.H., Stivaros S., van der Knaap M.S., et al. Recognizable phenotypes associated with intracranial calcification. Dev Med Child Neurol 2013, 55:46-57.
115. Nakajo A. Secondary hypertrophic osteoperiostosis with pernio. JDerm Urol 1939, 45:77-86.
116. Nishimura N., Deki T., Kato S. Hypertrophic pulmonary osteo-arthropathy with pernio-like eruption in the two families: report of the three cases. Jpn J Derm Venereol 1950, 60:136-141.
117. Megarbane A., Sanders A., Chouery E., et al. An unknown autoinflammatory syndrome associated with short stature and dysmorphic features in a young boy. JRheumatol 2002, 29:1084-1087.
118. Garg A., Hernandez M.D., Sousa A.B., et al. An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy. JClin Endocrinol Metab 2010, 95:E58-E63.
119. Torrelo A., Patel S., Colmenero I., et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. JAm Acad Dermatol 2010, 62:489-495.
120. Marrakchi S., Guigue P., Renshaw B.R., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. NEngl J Med 2011, 365:620-628.
121. Onoufriadis A., Simpson M.A., Pink A.E., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89:432-437.
122. Fuchs-Telem D., Sarig O., van Steensel M.A., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012, 91:163-170.
123. Jordan C.T., Cao L., Roberson E.D., et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet 2012, 90:784-795.
124. Blumberg H., Dinh H., Trueblood E.S., et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. JExp Med 2007, 204:2603-2614.
125. Medlej-Hashim M., Delague V., Chouery E., et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004, 5:4.
126. Habal N., Chen Y., Jordan C., et al. Pathogenesis Study of Infantile-Onset, Severe Pustular Psoriasis Reveals a De Novo Mutation in CARD14 Causing Psoriasis Which Responds Clinically to IL-12/23 Blocking Treatment with Ustekinumab. [abstract]. Arthritis Rheum 2011, 63(Suppl 10):310.
127. Glocker E.O., Kotlarz D., Boztug K., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. NEngl J Med 2009, 361:2033-2045.
128. Kotlarz D., Beier R., Murugan D., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012, 143:347-355.
129. Engelhardt K.R., Shah N., Faizura-Yeop I., et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. JAllergy Clin Immunol 2013, 131(3):825-830.
130. Boisson B., Laplantine E., Prando C., et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012, 13:1178-1186.